Clinical Trials
19 trialsNCT05277051 2026-05-22
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Active not recruiting
NCT06551142 2026-05-22
PanTumor-101
GlaxoSmithKline
Phase 1 Recruiting
NCT06796907 2026-05-22
BEHOLD-2
GlaxoSmithKline
Phase 1/2 Recruiting
NCT01042379 2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT04544995 2026-01-21
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
GlaxoSmithKline
Phase 1 Terminated
NCT02715284 2026-01-13
GARNET
Tesaro, Inc.
Phase 1 Active not recruiting
NCT03843359 2026-01-08
A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Active not recruiting
NCT06333314 2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2 Recruiting
NCT03307785 2025-11-25
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Tesaro, Inc.
Phase 1 Completed
NCT05980416 2025-11-14
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Elevation Oncology
Phase 1 Terminated
NCT02817633 2025-10-28
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Tesaro, Inc.
Phase 1 Active not recruiting
NCT04446351 2025-10-27
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Active not recruiting
NCT03981796 2025-09-03
RUBY
Tesaro, Inc.
Phase 3 Active not recruiting
NCT06926673 2025-07-03
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3
GlaxoSmithKline
Phase 2 Completed
NCT03739710 2025-06-15
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
GlaxoSmithKline
Phase 2 Completed
NCT02723955 2024-12-27
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GlaxoSmithKline
Phase 1 Completed
NCT05855811 2024-07-15
PREDOSTAR
Centre Leon Berard
Phase 2 Recruiting
NCT03250832 2024-04-11
CITRINO
Tesaro, Inc.
Phase 1 Completed
NCT03308942 2023-10-16
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
Tesaro, Inc.
Phase 2 Completed